



Liquidia Technologies to Provide Third Quarter 2018 Corporate Update on October 31, 2018

October 23, 2018

RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- [Liquidia Technologies, Inc. \(Nasdaq:LQDA\)](#) ("Liquidia"), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its [proprietary PRINT[®] technology](#) to transform the lives of patients, today announced that third quarter 2018 financial results will be reported on Wednesday, October 31, 2018. The company will host a webcast and conference call at 8 a.m. ET to provide a corporate update.

The live call may be accessed by dialing 1-877-707-8711 (domestic) and 1-857-270-6219 (international), and entering the conference code: 1695584. A live and archived webcast of the call will be available on the [Events & Presentations](#) page of the company's website.

About Liquidia Technologies

[Liquidia Technologies, Inc.](#) ("Liquidia") is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its [proprietary PRINT[®] technology](#) to transform the lives of patients. Currently, Liquidia is focused on the development of two product candidates using its PRINT[®] particle engineering platform: [LIQ861](#) for the treatment of pulmonary arterial hypertension and [LIQ865](#) for the treatment of local post-operative pain. Being evaluated in a Phase 3 clinical trial (INSPIRE), LIQ861, is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia's PRINT[®] technology. For more information visit our website at www.liquidia.com.

Contact:

Jennifer Almond
Director, Investor Relations & Corporate Communications
919.328.4389
IR@liquidia.com



Source: Liquidia Technologies, Inc.